Capricorn Fund Managers Ltd Makes New Investment in Enliven Therapeutics, Inc. $ELVN

Capricorn Fund Managers Ltd acquired a new stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 369,400 shares of the company’s stock, valued at approximately $14,480,000. Enliven Therapeutics comprises approximately 2.3% of Capricorn Fund Managers Ltd’s holdings, making the stock its 14th largest position.

Several other large investors also recently modified their holdings of ELVN. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Enliven Therapeutics by 25.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock worth $44,000 after acquiring an additional 594 shares in the last quarter. BNP Paribas Financial Markets increased its holdings in Enliven Therapeutics by 33.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock worth $75,000 after purchasing an additional 930 shares during the last quarter. Los Angeles Capital Management LLC purchased a new position in shares of Enliven Therapeutics during the 4th quarter valued at approximately $83,000. Quantbot Technologies LP grew its position in shares of Enliven Therapeutics by 47.1% during the second quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock worth $90,000 after buying an additional 1,434 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Enliven Therapeutics during the fourth quarter worth approximately $95,000. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, CFO Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $43.80, for a total value of $263,588.40. Following the transaction, the chief financial officer owned 51,000 shares of the company’s stock, valued at $2,233,800. The trade was a 10.55% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Lori Anne Kunkel sold 10,000 shares of the company’s stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $34.54, for a total transaction of $345,400.00. Following the sale, the director directly owned 51,884 shares of the company’s stock, valued at $1,792,073.36. This represents a 16.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 3.00% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the stock. Mizuho increased their price objective on shares of Enliven Therapeutics from $45.00 to $62.00 and gave the company an “outperform” rating in a research note on Tuesday, June 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Monday, April 20th. JonesTrading boosted their price objective on Enliven Therapeutics from $45.00 to $70.00 and gave the company a “buy” rating in a report on Monday. Wall Street Zen upgraded Enliven Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, May 11th. Finally, HC Wainwright lifted their target price on Enliven Therapeutics from $48.00 to $56.00 and gave the stock a “buy” rating in a research report on Thursday, March 26th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Enliven Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $64.50.

Enliven Therapeutics Trading Down 0.2%

Shares of Enliven Therapeutics stock opened at $50.73 on Wednesday. The stock has a market capitalization of $3.09 billion, a price-to-earnings ratio of -30.38 and a beta of 0.29. Enliven Therapeutics, Inc. has a twelve month low of $14.78 and a twelve month high of $52.39. The business’s 50 day simple moving average is $42.34 and its 200-day simple moving average is $32.98.

Enliven Therapeutics (NASDAQ:ELVN) last issued its earnings results on Thursday, May 7th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.06. Sell-side analysts predict that Enliven Therapeutics, Inc. will post -1.71 earnings per share for the current year.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.